<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03482297</url>
  </required_header>
  <id_info>
    <org_study_id>151008</org_study_id>
    <secondary_id>1R01HL144568-01A1</secondary_id>
    <nct_id>NCT03482297</nct_id>
  </id_info>
  <brief_title>Automated Abdominal Binder for Orthostatic Hypotension</brief_title>
  <official_title>Randomized, Double-blind, Sham-controlled to Evaluate the Effects of an Automated Abdominal Binder in Improving Orthostatic Tolerance in Autonomic Failure Patients With Disabling Orthostatic Hypotension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The automated inflatable abdominal binder is an investigational device for the treatment of&#xD;
      orthostatic hypotension (low blood pressure on standing) in patients with autonomic failure.&#xD;
      The purpose of this study is to determine safety and effectiveness of the automated abdominal&#xD;
      binder in improving orthostatic tolerance in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, sham-controlled, parallel group study to compare the&#xD;
      efficacy of the automated abdominal binder (inflated to 40 mm Hg) versus sham treatment&#xD;
      (abdominal binder inflated to 5 mm Hg) in improving orthostatic tolerance in patients with&#xD;
      primary autonomic failure disabled by orthostatic hypotension.&#xD;
&#xD;
      Potential participants will be admitted to the Vanderbilt Clinical Research Center for&#xD;
      evaluation of inclusion and exclusion criteria. Eligible patients will be randomized to the&#xD;
      active or sham binder group. Patients will then be asked to participate on three separate&#xD;
      study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day&#xD;
      for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with&#xD;
      active or sham binder combined with placebo pill t.i.d. The order of the study days will be&#xD;
      randomized. On each study day, blood pressure and heart rate will be measured while sitting,&#xD;
      lying down, standing and walking during the Morning Orthostatic Trial, and posture and&#xD;
      walking tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, sham-controlled, parallel-group, 3-study days inpatient study to compare the efficacy of the automated abdominal binder versus sham treatment in improving orthostatic tolerance in patients with primary autonomic failure disabled by neurogenic orthostatic hypotension.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patients and investigators will be blinded as to the experimental interventions (active or sham abdominal binder, and placebo or midodrine pills)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Orthostatic tolerance</measure>
    <time_frame>After 10 minutes of standing (or as tolerated) during the Morning orthostatic trial on the automated binder/sham study day</time_frame>
    <description>orthostatic tolerance is defined as the area under the curve of the upright systolic blood pressure (AUCSBP) during the Morning Orthostatic Trials</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Orthostatic Hypotension Symptom Assessment (OHSA) Score</measure>
    <time_frame>After 10 minutes of standing (or as tolerated) during the Morning orthostatic trial on the automated binder/sham study day</time_frame>
    <description>The Orthostatic Hypotension Symptom Assessment (OHSA) Score is the part I of the Orthostatic Hypotension Questionnaire (OHQ). It consists of six questions, each rating the intensity of one characteristic symptom of orthostatic hypotension: 1. Dizziness, lightheadedness, feeling faint, or feeling like you might black out; 2. Problems with vision (blurring, seeing spots, tunnel vision, etc.); 3. Generalized weakness; 4. Fatigue; 5. Trouble concentrating; and 6. Head/neck discomfort.The items are scored on an 11-point Likert scale from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst possible symptoms. Composite score is the average of the item scores obtained at the post-intervention stand period during the Morning Orthostatic Trials</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upright time</measure>
    <time_frame>After 10 minutes of standing and 15 minutes waking (as tolerated)</time_frame>
    <description>Sum of standing and walking times</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <condition>Autonomic Failure</condition>
  <condition>Pure Autonomic Failure</condition>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Automated Abdominal Binder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the automated abdominal binder combined with placebo pill t.i.d The automated abdominal binder will be placed during the morning orthostatic trial on the active/sham binder study day. The binder will inflate automatically (~40 mmHg) every time the participant stands up throughout the study day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham binder</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will be studied on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with the sham binder combined with placebo pill t.i.d. The sham binder will be placed during the morning orthostatic trial on the active/sham binder study day. The sham binder will inflate automatically (~5 mmHg) every time the participant stands up throughout the study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>automated abdominal binder</intervention_name>
    <description>The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.</description>
    <arm_group_label>Automated Abdominal Binder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham binder</intervention_name>
    <description>The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.</description>
    <arm_group_label>Sham binder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo will be given three times a day on the baseline day (placebo)</description>
    <arm_group_label>Automated Abdominal Binder</arm_group_label>
    <arm_group_label>Sham binder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>A midodrine pill 10mg will be given three times a day on the standard of care study day</description>
    <arm_group_label>Automated Abdominal Binder</arm_group_label>
    <arm_group_label>Sham binder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, age 40-80 years.&#xD;
&#xD;
          -  Possible or probable Multiple Systems Atrophy and Pure Autonomic Failure as defined by&#xD;
             Consensus Criteria.&#xD;
&#xD;
          -  Neurogenic orthostatic hypotension defined as a â‰¥30-mm Hg decrease in SBP within 3&#xD;
             minutes of standing associated with impaired autonomic reflexes determined by&#xD;
             autonomic testing in the absence of other identifiable causes, and&#xD;
&#xD;
          -  Moderate to severe orthostatic symptoms, defined as an Orthostatic Hypotension Symptom&#xD;
             Assessment (OHSA) composite score â‰¥4 (self-rating Likert scale of 0 to 10, with 0&#xD;
             reflecting absence of symptoms), within the first 10 minutes of the screening&#xD;
             orthostatic stress test, and that have an impact in quality of life, as defined by the&#xD;
             patient.&#xD;
&#xD;
          -  Able and willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Systemic illnesses known to produce autonomic neuropathy, including but not limited to&#xD;
             diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies.&#xD;
&#xD;
          -  History of known aortic aneurisms, thoracic, abdominal or pelvic surgery in the past 6&#xD;
             months; symptomatic abdominal or inguinal hernias; severe gastroesophageal reflux;&#xD;
             recent fractures or fissures of ribs, thoracic or lumbar spine; medical devices&#xD;
             implanted on the abdominal wall or abdomen that would interfere with the binder; known&#xD;
             abdominal or pelvic tumors, cysts or enlarged spleen; intolerance to any increase in&#xD;
             intraabdominal pressure.&#xD;
&#xD;
          -  Pre-existing sustained supine hypertension â‰¥180/110.&#xD;
&#xD;
          -  Bedridden patients or those who are unable to stand due to motor impairment or severe&#xD;
             orthostatic hypotension.&#xD;
&#xD;
          -  Clinically unstable coronary artery disease (recurrent angina despite medical&#xD;
             therapy), or major cardiovascular or neurological event in the past 6 months&#xD;
             (myocardial infarction, stroke or transient ischemic attacks).&#xD;
&#xD;
          -  Concomitant use of anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine and Pharmacology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis E Okamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily C Smith, RN</last_name>
    <phone>615.875.1516</phone>
    <email>autonomics@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Okamoto, MD</last_name>
    <phone>615-936-6119</phone>
    <email>autonomics@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Autonomic Dysfunction Center/ Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Okamoto, MD</last_name>
      <phone>615-936-6119</phone>
      <email>autonomics@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Andre Diedrich, MD PhD</last_name>
      <phone>615-936-0454</phone>
      <email>autonomics@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bonnie K Black, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis E Okamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Italo Biaggioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Diedrich, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily C Smith, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Gamboa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Luis E Okamoto</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>orthostatic hypotension</keyword>
  <keyword>abdominal binder</keyword>
  <keyword>pure autonomic failure</keyword>
  <keyword>multiple system atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

